NCT00332891View on ClinicalTrials.gov

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

508

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Anxiety Disorders
Interventions
DRUG

SR58611A

Trial Locations (5)

Unknown

Sanofi-Aventis Administrative Office, Sofia

Sanofi-Aventis Administrative Office, Zagreb

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Belgrade

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00332891 - An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder | Biotech Hunter | Biotech Hunter